Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data – a database study in the British population
DOKPE
- Mellenthin, Claudia ORCID University of Fribourg
- Meier, Christoph ORCID University of Basel
- Jick, Susan ORCID Boston University School of Public Health
- Bühler, Leo Hans University of Fribourg
- Adamina, Michel University of Fribourg
- Schneider, Cornelia University of Basel
- 2025
Published in:
- Pancreatology. - Elsevier BV. - 2025
English
Introduction
New onset diabetes (NOD) can be a first symptom of pancreatic ductal adenocarcinoma (PDAC), but less than 1 % of NOD are caused by PDAC. The EndPAC score tests for PDAC risk in NOD patients. As necessary information is often missing, the aim of our study was to assess the performance of the score using methods that adjust for missing values so the score can be successfully applied to all patients.
Patients/methods
We retrospectively followed a British cohort with NOD in the Clinical Practice Research Datalink until they developed PDAC or were censored. We calculated the EndPAC score in all patients and assessed its performance with different imputation methods for missing values. We calibrated the score for the British population.
Results
We included 197′092 NOD patients. PDAC occurred in 901 cases within 3 years after the diabetes diagnosis. Complete information to calculate the EndPAC score was available for 9.2 % of the patients. In those, the AUC (Area under the Receiver Operating Curve) of the original EndPAC score was 0.76. Including all patients, using the imputation of the population median for missing values, the AUC was 0.69. It improved to 0.71 after calibration to the UK population.
Conclusions
Use of imputation methods enabled us to use the EndPAC score for all NOD patients. However, use of the EndPAC score alone is still not sufficient to select NOD patients for diagnostic workup, with or without complete information. Its use in combination with a biomarker might lead to a better risk-benefit ratio.
New onset diabetes (NOD) can be a first symptom of pancreatic ductal adenocarcinoma (PDAC), but less than 1 % of NOD are caused by PDAC. The EndPAC score tests for PDAC risk in NOD patients. As necessary information is often missing, the aim of our study was to assess the performance of the score using methods that adjust for missing values so the score can be successfully applied to all patients.
Patients/methods
We retrospectively followed a British cohort with NOD in the Clinical Practice Research Datalink until they developed PDAC or were censored. We calculated the EndPAC score in all patients and assessed its performance with different imputation methods for missing values. We calibrated the score for the British population.
Results
We included 197′092 NOD patients. PDAC occurred in 901 cases within 3 years after the diabetes diagnosis. Complete information to calculate the EndPAC score was available for 9.2 % of the patients. In those, the AUC (Area under the Receiver Operating Curve) of the original EndPAC score was 0.76. Including all patients, using the imputation of the population median for missing values, the AUC was 0.69. It improved to 0.71 after calibration to the UK population.
Conclusions
Use of imputation methods enabled us to use the EndPAC score for all NOD patients. However, use of the EndPAC score alone is still not sufficient to select NOD patients for diagnostic workup, with or without complete information. Its use in combination with a biomarker might lead to a better risk-benefit ratio.
- Faculty
- Faculté des sciences et de médecine
- Department
- Section de médecine
- Language
-
- English
- Classification
- Pathology, clinical medicine
- License
-
CC BY-NC-ND
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.pan.2025.09.017
- ISSN 1424-3903
- Persistent URL
- https://folia.unifr.ch/unifr/documents/332881
Statistics
Document views: 35
File downloads:
- 1-s2.0-s142439032500626x-main: 92